Standard of care

Zymeworks Announces Participation in Upcoming Investor Conferences

Retrieved on: 
Tuesday, February 27, 2024
Standard of care, Conference, Pharmaceutical industry

VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:

Key Points: 
  • VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:
    TD Cowen 44th Annual Health Care Conference: Zymeworks’ management will participate in one-on-one meetings and present on March 6th at 11:10 am Eastern Time (ET) in Boston, MA.
  • Barclays 26th Annual Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on March 14th at 11:45 am ET in Miami, FL.

PolarityTE Announces First Subject Screened in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers

Retrieved on: 
Monday, February 26, 2024
Incidence, PAR, Doctor of Philosophy, Aes, RV1, MD, Ulcer, Hospital, Standard of care, Amputation, Death, Patient, United, SALSA, Tissue, SOC, Pharmaceutical industry

Subjects will be randomized to one of two treatment groups, receiving either SkinTE plus the standard of care (SOC) or the SOC alone.

Key Points: 
  • Subjects will be randomized to one of two treatment groups, receiving either SkinTE plus the standard of care (SOC) or the SOC alone.
  • The primary endpoint is the incidence of DFUs closed at 12 weeks.
  • COVER DFUS II is a pivotal study that PolarityTE will conduct under its open IND for SkinTE.
  • We are excited to evaluate how the optimized healthy cells from the patient in SkinTE can facilitate closure in these difficult-to-treat ulcers.

IR-MED Reports 92% Efficacy for PressureSafe™ in Early, Non-Invasive, Skin Color Agnostic Detection of Pressure Injuries

Retrieved on: 
Tuesday, February 20, 2024
PHD, Incidence, HMO, Principal, Inflammation, Pressure, Calibration, Infrared, Skin, Methodism, Standard of care, Conference, Safety, Nursing, Biomarker, Rabin Medical Center, Patient, Clalit Health Services, CSO, Diagnosis, Trial of the century, Medical device

The objective of the study was to evaluate the sensitivity, specificity, and usability of PressureSafe to detect early-stage pressure injuries Stage 1 / suspected deep tissue injuries (sDTI) before skin breakage, compared to standard of care.

Key Points: 
  • The objective of the study was to evaluate the sensitivity, specificity, and usability of PressureSafe to detect early-stage pressure injuries Stage 1 / suspected deep tissue injuries (sDTI) before skin breakage, compared to standard of care.
  • PressureSafe detected biomarkers and changes in tissue structures under the skin’s surface as they relate to pressure injuries.
  • The 14-day efficacy portion of the single arm, bi-center study evaluated 38 patients at high risk of pressure injury development.
  • Based on these data, the study concluded that PressureSafe is a safe, efficient, and valuable method for early detection of pressure injuries.

RenovoRx Highlights Key Leadership Promotions

Retrieved on: 
Friday, March 8, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, CPA, Strategic planning, Growth, Standard of care, Safety, LAPC, Phase, Controller, Financial management, Research

(“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today highlighted the recent key leadership promotions of Leesa Gentry to Chief Clinical Officer and Ronald B. Kocak, CPA to Principal Accounting Officer.

Key Points: 
  • (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today highlighted the recent key leadership promotions of Leesa Gentry to Chief Clinical Officer and Ronald B. Kocak, CPA to Principal Accounting Officer.
  • Since joining RenovoRx, Ms. Gentry has demonstrated exemplary leadership and commitment to advancing the Company’s clinical pipeline.
  • Mr. Kocak has been promoted to the position of Principal Accounting Officer and will retain his roles as Vice President and Controller of RenovoRx.
  • In this new leadership role, Mr. Kocak will oversee all financial management, reporting and strategic planning initiatives crucial to furthering the Company’s research and development efforts.

Soleo Health Celebrates 10 Years of Simplifying Complex Care for Patients

Retrieved on: 
Thursday, March 7, 2024
Oncology, Research, Software, Medical Devices, Infectious Diseases, Hospitals, Genetics, Fitness & Nutrition, Science, Technology, Clinical Trials, Nursing, Cardiology, Medical Supplies, Biotechnology, FDA, Surgery, Diabetes, AIDS, Insurance, Health, Professional Services, Practice Management, Managed Care, Other Health, General Health, Radiology, Pharmaceutical, Pharmacy, Standard of care, Patient, Hospital

Soleo Health , a national leader in complex specialty pharmacy services, recently marked its 10th anniversary on February 24, 2024.

Key Points: 
  • Soleo Health , a national leader in complex specialty pharmacy services, recently marked its 10th anniversary on February 24, 2024.
  • Led by Chief Executive Officer Drew Walk and Chief Commercial Officer Craig Vollmer, Soleo Health was founded on the commitment to simplify complex care for patients.
  • Over the past decade, Soleo Health has become one of the fastest-growing independent specialty pharmacies, solidifying its position as a leading provider of complex specialty pharmacy services.
  • “Looking ahead, we remain dedicated to defining the unique requirements of complex specialty pharmacy, focusing on patients with complex, rare and ultra-rare diseases,” explained Walk.

Caregility to Showcase the “Intelligent Hospital Room of the Future” at HIMSS24

Retrieved on: 
Thursday, March 7, 2024
Nursing, Health, Technology, Hospitals, Telemedicine, Virtual Medicine, Artificial Intelligence, Hospital, LanguageLine Solutions, Multimedia, AI, Patient satisfaction, Future, Standard of care, Conference, Stethoscope, Exhibition, Patient, Patient safety, Heart, Electronic health record, Medical imaging

Caregility, a pioneer in enterprise telehealth solutions, is excited to showcase its Intelligent Hospital Room of the Future at the 2024 HIMSS Global Health Conference & Exhibition , taking place in Orlando, Florida, March 11-15.

Key Points: 
  • Caregility, a pioneer in enterprise telehealth solutions, is excited to showcase its Intelligent Hospital Room of the Future at the 2024 HIMSS Global Health Conference & Exhibition , taking place in Orlando, Florida, March 11-15.
  • Responsible AI enhancements that augment patient safety, clinical insight, and operational value using computer vision, radar-based sensors, and sound analytics.
  • As part of the exhibit, Caregility will demonstrate its first dual-camera telehealth edge device, the new APS200 Duo, for the first time.
  • HIMSS24 attendees are invited to tour the Intelligent Hospital Room of the Future at Caregility booth 4121 to learn more about how health systems are transforming the future of healthcare delivery through hybrid care enablement.

Nalu Medical, Inc. Closes $85 Million Series E Round

Retrieved on: 
Tuesday, March 5, 2024
Neurology, Biotechnology, Nanotechnology, Surgery, Health, Medical Devices, Health Technology, Technology, Pura, Medicine, Neuropathic pain, PNS, General partnership, Physician, Novo, Spinal cord stimulator, Standard of care, Health care, Chronic pain, Patient, SCS

Nalu Medical, Inc. (Nalu), a private company focused on innovative, minimally invasive, and non-pharmacologic solutions for chronic neuropathic pain, announced today the closing of an incremental $20M in equity financing from new investor B Capital, bringing the total Series E round of equity investment to $85M.

Key Points: 
  • Nalu Medical, Inc. (Nalu), a private company focused on innovative, minimally invasive, and non-pharmacologic solutions for chronic neuropathic pain, announced today the closing of an incremental $20M in equity financing from new investor B Capital, bringing the total Series E round of equity investment to $85M.
  • Series E was led by Novo Holdings (Novo) with $65M of the total closing in late-December 2023.
  • Also participating in the round were all existing significant investors: Gilde Healthcare, MVM Partners, Endeavour Vision, Decheng Capital, Longitude Capital, Advent Life Sciences, Pura Vida, and Aperture Venture Partners.
  • “The Nalu Team is committed to addressing the unmet needs of patients suffering from chronic intractable neuropathic pain.

Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

Retrieved on: 
Tuesday, March 5, 2024
Health Technology, Diabetes, Manufacturing, Technology, Pharmaceutical, Other Consumer, General Health, Medical Devices, Clinical Trials, Wearables, Mobile Technology, Other Manufacturing, Science, Consumer, Health, Research, Real-World Evidence, Cloud, OBE, Adolescence, Doctor of Philosophy, Treatment, Medical director, Database, University, Hypoglycemia, Associate, AID, University of Liverpool, Standard of care, Data, Therapy, Insulin, Convention, Randomized controlled trial, CGM, Pathway, Use, Conference, MDI, Automation, Endocrinology, MD, DASH, ATTD, Medicare, University of Edinburgh, Edge Hill University, Corporation, Chairperson, Medical device

“We are thrilled to unveil the results of our inaugural randomized controlled trial with groundbreaking insights from international Omnipod 5 users,” said Dr. Trang Ly MBBS, FRACP, PhD, Insulet Senior Vice President and Medical Director.

Key Points: 
  • “We are thrilled to unveil the results of our inaugural randomized controlled trial with groundbreaking insights from international Omnipod 5 users,” said Dr. Trang Ly MBBS, FRACP, PhD, Insulet Senior Vice President and Medical Director.
  • It is the first Omnipod 5 randomized controlled trial to date, and the first time the system has been evaluated in participants living outside of the United States.
  • This presentation will take place on Thursday, March 7 at 12:00 p.m. CET and Friday, March 8 at 10:30 a.m. CET.
  • Insulet representatives will be available to provide Omnipod product demonstrations to conference attendees, offering healthcare professionals the chance to experience Omnipod DASH and Omnipod 5 first-hand.

Therapeutic Solutions International Announces Landmark Finding Regarding Mechanism of Action of its JadiCell Stem Cell Product

Retrieved on: 
Thursday, February 29, 2024
Health, Stem Cells, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, FDA, TSOI, Standard of care, Cell, GM-CSF, Safety, COVID-19, Patent, Patient, Monocyte, Acute respiratory distress syndrome, Survival, Phase, Science, TGF, Brain, Pharmaceutical industry

Depletion of either of these cells significantly reduced therapeutic effects of JadiCells.

Key Points: 
  • Depletion of either of these cells significantly reduced therapeutic effects of JadiCells.
  • Additionally, transfer of monocytes and T cells from JadiCell treated mice was able to protect naïve mice from lung injury.
  • The therapeutic effect of JadiCells was amplified by administration of Leukine (GM-CSF), which is known to increase circulating monocytes.
  • We are dedicated to curing this terrible disease1 and making our cells the new standard of care.”

Blue Earth Therapeutics Announces Participation in Upcoming B. Riley Securities Radiopharma Investor Conference

Retrieved on: 
Wednesday, February 28, 2024
Biotechnology, Pharmaceutical, Health, Radiopharmaceutical, Therapy, Medicine, Conference, RLT, Standard of care

Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced that it will be presenting at the upcoming B. Riley Securities’ Radiopharma Investor Conference.

Key Points: 
  • Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced that it will be presenting at the upcoming B. Riley Securities’ Radiopharma Investor Conference.
  • Phil., Chief Executive Officer of Blue Earth Diagnostics and Blue Earth Therapeutics, will present an overview of Blue Earth Therapeutics from 8:00 – 8:30 a.m.
  • ET and participate in an expert panel discussion, “Opportunities and Challenges in 2024, Perspectives from Leaders in Radiopharma,” from 9:15 – 9:50 a.m.
  • “Blue Earth Therapeutics continues to expand our leadership position in the rapidly growing area of radiopharmaceuticals,” said David Gauden., D.Phil., Chief Executive Officer of the Company.